Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
9 studies found for:    "Post-transplant lymphoproliferative disease"
Show Display Options
Rank Status Study
1 Completed Fludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD)
Conditions: Post-transplant Lymphoproliferative Disease (PTLD);   Non Burkitt
Intervention: Drug: fludarabine, cyclophosphamide, doxorubicin, rituximab
2 Recruiting Bortezomib Plus Rituximab for EBV+ PTLD
Conditions: Post-transplant Lymphoproliferative Disease;   Solid Organ Transplant;   Stem Cell Transplant (Bone Marrow Transplant);   Epstein Barr Virus Infections
Interventions: Drug: bortezomib;   Drug: rituximab
3 Recruiting Phase II of Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma
Conditions: Epstein Barr Virus Associated Non Hodgkin's Lymphoma;   Epstein Barr Virus Associated Hodgkin's Lymphoma;   Post-Transplant Lymphoproliferative Disease
Interventions: Drug: Doxorubicin;   Drug: Methotrexate;   Drug: Leucovorin;   Biological: Hydroxyurea;   Drug: Zidovudine;   Procedure: Urine Alkalization
4 Not yet recruiting Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy
Condition: Posttransplant Lymphoproliferative Disorder
Interventions: Drug: Rituximab sc;   Drug: Rituximab sc consolidation;   Drug: Rituximab sc combined with CHOP chemotherapy;   Drug: Rituximab sc combined with alternating chemotherapy with CHOP and DHAOx
5 Terminated Relationship Between EBV and PTLD
Condition: Pediatric Heart Transplant
Intervention:
6 Unknown  Reduced Immunosuppressive Therapy With or Without Donor White Blood Cells in Treating Patients With Lymphoproliferative Disease After Organ Transplantation
Condition: Lymphoproliferative Disorder
Intervention: Biological: therapeutic allogeneic lymphocytes
7 Completed Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder
Conditions: Post-transplant Lymphoproliferative Disorder;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Waldenström Macroglobulinemia
Interventions: Biological: rituximab;   Radiation: indium In 111 ibritumomab tiuxetan;   Radiation: yttrium Y 90 ibritumomab tiuxetan
8 Terminated Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation
Conditions: Leukemia;   Lymphoma;   Lymphoproliferative Disorder
Interventions: Biological: beta-glucan;   Biological: rituximab
9 Active, not recruiting
Has Results
Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation
Condition: Lymphoproliferative Disorder
Interventions: Biological: rituximab;   Drug: cyclophosphamide;   Drug: methylprednisolone;   Drug: prednisone

Indicates status has not been verified in more than two years